IVA vs PRQR
Inventiva S.a. and ProQR Therapeutics N.v., side by side — 4 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | IVA | PRQR |
|---|---|---|
| Revenue | €9.2M | €15.9M |
| Net income | €-184.2M | €-42.2M |
| Gross margin | · | · |
| Net margin | · | −265.2% |
| Return on equity | · | −61.2% |
| Diluted EPS | −€3.08 | −€0.40 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | €-53.8M |
| Equity | · | €49.4M |
| Net debt / equity | · | −1.77× |
| Current ratio | 0.92× | 3.09× |
| Revenue CAGR 5y | 5.6% | · |
| Profit CAGR 5y | · | · |
PRQR bills 1.7× the revenue of IVA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
4 years side by side
| Fiscal year | IVA | PRQR |
|---|---|---|
| FY2024 | €9.2M | €18.9M |
| FY2023 | €17.5M | €6.5M |
| FY2022 | €12.2M | €3.6M |
| FY2021 | €4.2M | €1.3M |
Bottom line
| Fiscal year | IVA | PRQR |
|---|---|---|
| FY2024 | €-184.2M | €-27.8M |
| FY2023 | €-110.4M | €-28.1M |
| FY2022 | €-54.3M | €-64.4M |
| FY2021 | €-49.6M | €-60.7M |
Standard deviation, each side
IVA's return on equity has been more volatile than PRQR's over the 5 comparable fiscal years — 12.7 percentage points of standard deviation against 6.2.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between IVA and PRQR over these 5 fiscal years — IVA led in 4 and PRQR in 1.
5 of 11 comparable fiscal years — a year missing data on either side is not counted.